Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 3140983, 12 pages
https://doi.org/10.1155/2018/3140983
Review Article

Liver Illness and Psoriatic Patients

1Department of Anaesthesiological, Surgical and Emergency Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy
2Department of Medicine, Division of Infectious Diseases, “San Giuseppe Moscati” Hospital, Avellino, Italy
3Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
4Department of Pathophysiology and Transplantation, Dermatology Unit, IRCCS Ca' Granda, University of Milan, Milan, Italy
5Study Center of Young Dermatologists Italian Network (YDIN), Bergamo, Italy

Correspondence should be addressed to Marco Fiore; ti.liamtoh@eroif.ocram and Sebastiano Leone; ti.oohay@enoelonaitsabes

Received 31 August 2017; Revised 30 October 2017; Accepted 4 January 2018; Published 6 February 2018

Academic Editor: Dimitrios P. Bogdanos

Copyright © 2018 Marco Fiore et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Parisi, D. P. M. Symmons, C. E. M. Griffiths, and D. M. Ashcroft, “Global epidemiology of psoriasis: a systematic review of incidence and prevalence,” Journal of Investigative Dermatology, vol. 133, no. 2, pp. 377–385, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. C. E. M. Griffiths, J. M. van der Walt, D. M. Ashcroft et al., “The global state of psoriasis disease epidemiology: a workshop report,” British Journal of Dermatology, vol. 177, no. 1, pp. e4–e7, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. J. E. Greb, A. M. Goldminz, J. T. Elder et al., “Psoriasis,” Nature Reviews Disease Primers, vol. 2, Article ID 16082, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. N. O. Al-Harbi, A. Nadeem, M. M. Al-Harbi et al., “Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model,” Immunobiology, vol. 222, no. 2, pp. 128–136, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Mancini, E. Amorotti, S. Vecchio, M. P. de Leon, and L. Roncucci, “Infliximab-related hepatitis: Discussion of a case and review of the literature,” Internal and Emergency Medicine, vol. 5, no. 3, pp. 193–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Tula, T. Ergun, D. Seckin, Z. Ozgen, and E. Avsar, “Psoriasis and the liver: problems, causes and course,” Australasian Journal of Dermatology, vol. 58, no. 3, pp. 194–199, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. P. S. Helliwell and W. J. Taylor, “Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - Comparison of drugs and adverse reactions,” The Journal of Rheumatology, vol. 35, no. 3, pp. 472–476, 2008. View at Google Scholar · View at Scopus
  8. L. C. Ng, Y. Y. Lee, C. K. Lee, and S.-M. Wong, “A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia,” International Journal of Dermatology, vol. 52, no. 1, pp. 102–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Amital, Y. Arnson, G. Chodick, and V. Shalev, “Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate,” Rheumatology, vol. 48, no. 9, pp. 1107–1110, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Tilling, S. Townsend, and J. David, “Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis,” Clinical Drug Investigation, vol. 26, no. 2, pp. 55–62, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. B. E. Strober and K. Menon, “Folate supplementation during methotrexate therapy for patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 53, no. 4, pp. 652–659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. De, T. Sen, and M. Chatterjee, “Reduction of oxidative stress by an ethanolic extract of leaves of Piper betle (Paan) Linn. decreased methotrexate-induced toxicity,” Molecular and Cellular Biochemistry, vol. 409, no. 1-2, pp. 191–197, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Rademaker, M. Gupta, M. Andrews et al., “The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting,” Australasian Journal of Dermatology, vol. 58, no. 3, pp. 166–170, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Galíndez and L. Carmona, “Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?” Reumatología Clínica, vol. 12, no. 6, pp. 307–312, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Gisondi, M. Del Giglio, and G. Girolomoni, “Considerations for Systemic Treatment of Psoriasis in Obese Patients,” American Journal of Clinical Dermatology, vol. 17, no. 6, pp. 609–615, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Curtis, T. Beukelman, A. Onofrei et al., “Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 43–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. M. Yeo, V. H. Chong, A. Earnest, and W. L. Yang, “Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis,” World Journal of Hepatology, vol. 5, no. 5, pp. 275–280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Castera, “Noninvasive Assessment of Liver Fibrosis,” Digestive Diseases, vol. 33, no. 4, pp. 498–503, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Lynch, E. Higgins, P. A. McCormick et al., “The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis,” JAMA Dermatology, vol. 150, no. 8, pp. 856–862, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. K. E. Lowenthal, P. J. Horn, and R. E. Kalb, “Concurrent use of methotrexate and acitretin revisited,” Journal of Dermatological Treatment, vol. 19, no. 1, pp. 22–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J. An, D. Zhang, J. Wu et al., “The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis,” Pharmacological Research, vol. 121, pp. 158–168, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Roenigk H.H., J. P. Callen, C. A. Guzzo et al., “Effects of acitretin on the liver,” Journal of the American Academy of Dermatology, vol. 41, no. 4, pp. 584–588, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. F. S. G. Silva, M. P. C. Ribeiro, M. S. Santos, P. Rocha-Pereira, A. Santos-Silva, and J. B. A. Custódio, “Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity,” Toxicology, vol. 306, pp. 93–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. V. M. R. Heydendael, P. I. Spuls, B. C. Opmeer et al., “Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis,” The New England Journal of Medicine, vol. 349, no. 7, pp. 658–665, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Korolczuk, K. Caban, M. Amarowicz, G. Czechowska, and J. Irla-Miduch, “Oxidative Stress and Liver Morphology in Experimental Cyclosporine A-Induced Hepatotoxicity,” BioMed Research International, vol. 2016, Article ID 5823271, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. J. B. French, M. Bonacini, M. Ghabril, D. Foureau, and H. L. Bonkovsky, “Hepatotoxicity associated with the use of anti-TNF-α agents,” Drug Safety, vol. 39, no. 3, pp. 199–208, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Llamas-Velasco, M. J. Concha-Garzón, A. García-Diez, and E. Daudén, “Liver injury in psoriasis patients receiving ustekinumab: A retrospective study of 44 patients treated in the clinical practice setting,” Actas Dermo-Sifiliográficas, vol. 106, no. 6, pp. 470–476, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. W. I. Cheung, M. L. Tse, T. Ngan et al., “Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine,” Clinical Toxicology, vol. 47, no. 7, pp. 683–685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Bergman and J. Schjott, “Hepatitis caused by Lotus-f3?” Basic & Clinical Pharmacology & Toxicology, vol. 104, no. 5, pp. 414–416, 2009. View at Publisher · View at Google Scholar
  30. A. M. Mahmoud, O. E. Hussein, W. G. Hozayen, and S. M. Abd El-Twab, “Methotrexate hepatotoxicity is associated with oxidative stress, and down-regulation of PPARγ and Nrf2: Protective effect of 18β-Glycyrrhetinic acid,” Chemico-Biological Interactions, vol. 270, pp. 59–72, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. H. I. Katz, J. Waalen, and E. E. Leach, “Acitretin in psoriasis: An overview of adverse effects,” Journal of the American Academy of Dermatology, vol. 41, no. 3, p. -S12, 1999. View at Google Scholar · View at Scopus
  32. Z.-J. Li, A. Abulizi, G.-L. Zhao et al., “Bakuchiol Contributes to the Hepatotoxicity of Psoralea corylifolia in Rats,” Phytotherapy Research, vol. 31, no. 8, pp. 1265–1272, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. European Association for the Study of the Liver, “EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection,” Journal of Hepatology, vol. 67, no. 2, pp. 370–398, 2017. View at Google Scholar
  34. R. Orlando, M. Foggia, and AE. Maraolo, “Prevention of hepatitis B virus infection: from the past to the future,” European Journal Microbiology Infectious Diseases, vol. 34, no. 6, pp. 1059–1070, 2015. View at Publisher · View at Google Scholar
  35. G. Raimondo, J.-P. Allain, M. R. Brunetto et al., “Statements from the Taormina expert meeting on occult hepatitis B virus infection,” Journal of Hepatology, vol. 49, no. 4, pp. 652–657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. R. Kappus and R. K. Sterling, “Extrahepatic manifestations of acute hepatitis B virus infection,” Journal of Gastroenterology and Hepatology, vol. 9, no. 2, pp. 123–126, 2013. View at Google Scholar · View at Scopus
  37. R. P. Perrillo, P. Martin, and A. S. Lok, “Preventing hepatitis B reactivation due to immunosuppressive drug treatments,” Journal of the American Medical Association, vol. 313, no. 16, pp. 1617-1618, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. S. A. Gonzalez and R. P. Perrillo, “Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy,” Clinical Infectious Diseases, vol. 62, pp. S306–S313, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Tavakolpour, S. M. Alavian, and S. Sali, “Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: A comprehensive review-screened,” Hepatitis Monthly, vol. 16, no. 4, Article ID e35810, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. J. P. Hwang and A. S.-F. Lok, “Management of patients with hepatitis B who require immunosuppressive therapy,” Nature Reviews Gastroenterology & Hepatology, vol. 11, no. 4, pp. 209–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Sandherr, M. Hentrich, M. von Lilienfeld-Toal et al., “Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO),” Annals of Hematology, vol. 94, no. 9, pp. 1441–1450, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Bessone and M. Dirchwolf, “Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations,” World Journal of Hepatology, vol. 8, no. 8, pp. 385–394, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Loomba and T. J. Liang, “Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions,” Gastroenterology, vol. 152, no. 6, pp. 1297–1309, 2017. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Pattullo, “Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure,” World Journal of Hepatology, vol. 7, no. 7, pp. 954–967, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. R. P. Perrillo, R. Gish, and Y. T. Falck-Ytter, “American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy,” Gastroenterology, vol. 148, no. 1, pp. 221–244.e3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Daudén, L. Puig, C. Ferrándiz, J. L. Sánchez-Carazo, and J. M. Hernanz-Hermosa, “Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology,” Journal of the European Academy of Dermatology and Venereology, vol. 30, pp. 1–18, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. C. S. Lee and J. Koo, “A review of acitretin, a systemic retinoid for the treatment of psoriasis,” Expert Opinion on Pharmacotherapy, vol. 6, no. 10, pp. 1725–1734, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Nast, A. Jacobs, S. Rosumeck, and R. Werner, “Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris - update 2015 - EDF in cooperation with EADV and IPC,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 12, pp. e1–e22, 2015. View at Publisher · View at Google Scholar
  49. C. Bonifati, V. Lora, D. Graceffa, and L. Nosotti, “Management of psoriasis patients with hepatitis B or hepatitis C virus infection,” World Journal of Gastroenterology, vol. 22, no. 28, pp. 6444–6455, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Minozzi, S. Bonovas, T. Lytras et al., “Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis, Expert Opinion Safety,” in Expert Opinion on Drug Safety, vol. 15, supplement 1, pp. 11–34, 2016. View at Google Scholar
  51. M. B. Carroll and M. I. Bond, “Use of Tumor Necrosis Factor-α Inhibitors in Patients with Chronic Hepatitis B Infection,” Seminars in Arthritis and Rheumatism, vol. 38, no. 3, pp. 208–217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Pérez-Alvarez, C. Díaz-Lagares, F. García-Hernández et al., “Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases,” Medicine, vol. 90, no. 6, pp. 359–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Abramson, A. Menter, and R. Perrillo, “Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management,” Journal of the American Academy of Dermatology, vol. 67, no. 6, pp. 1349–1361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Prignano, F. Ricceri, L. Pescitelli, F. Zanieri, and T. Lotti, “Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients,” British Journal of Dermatology, vol. 164, no. 3, pp. 645–647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Cassano, V. Mastrandrea, M. Principi et al., “Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease,” Journal of Biological Regulators and Homeostatic Agents, vol. 25, no. 2, pp. 285–289, 2011. View at Google Scholar · View at Scopus
  56. S. Piaserico, P. Dapavo, A. Conti, P. Gisondi, and F. P. Russo, “Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: A multicentre cohort study of 37 patients and review of the literature,” Journal of the European Academy of Dermatology and Venereology, 2017. View at Publisher · View at Google Scholar · View at Scopus
  57. Y.-T. Cho, C.-H. Chen, H.-Y. Chiu, and T.-F. Tsai, “Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan,” The Journal of Dermatology, vol. 39, no. 3, pp. 269–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Conde-Taboada, J. P. Muñoz, L. Campos Muñoz, and E. López-Bran, “Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection,” Journal of the American Academy of Dermatology, vol. 60, no. 6, pp. 1077–1080, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Thaçi, A. Blauvelt, K. Reich et al., “Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial,” Journal of the American Academy of Dermatology, vol. 73, no. 3, pp. 400–409, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. Z. Huang, J. C. van Velkinburgh, B. Ni, and Y. Wu, “Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B,” Liver International, vol. 32, no. 6, pp. 894–901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Blauvelt, “Safety of secukinumab in the treatment of psoriasis,” Expert Opinion on Drug Safety, vol. 15, no. 10, pp. 1413–1420, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Motaparthi, V. Stanisic, A. S. Van Voorhees, M. G. Lebwohl, and S. Hsu, “From the medical board of the national psoriasis foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 70, no. 1, pp. 178–186, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. L. C. Coates, R. Murphy, and P. S. Helliwell, “New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation,” British Journal of Dermatology, vol. 174, no. 6, pp. 1174–1178, 2016. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Ramiro, J. S. Smolen, R. Landewé et al., “Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 75, no. 3, pp. 490–498, 2016. View at Publisher · View at Google Scholar
  65. D. P. Webster, P. Klenerman, J. Collier, and K. J. Jeffery, “Development of novel treatments for hepatitis C,” The Lancet Infectious Diseases, vol. 9, no. 2, pp. 108–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Dedania and G. Y. Wu, “Dermatologic extrahepatic manifestations of hepatitis C,” Journal of Clinical and Translational Hepatology, vol. 3, no. 2, pp. 127–133, 2015. View at Publisher · View at Google Scholar
  67. P. Cacoub, L. Gragnani, C. Comarmond, and A. L. Zignego, “Extrahepatic manifestations of chronic hepatitis C virus infection,” Digestive and Liver Disease, vol. 46, pp. S165–S173, 2014. View at Publisher · View at Google Scholar
  68. A. D. Cohen, D. Weitzman, S. Birkenfeld, and J. Dreiher, “Psoriasis associated with hepatitis C but not with hepatitis B,” Dermatology, vol. 220, no. 3, pp. 218–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. D. P. Bogdanos and L. I. Sakkas, “From microbiome to infectome in autoimmunity,” Current Opinion in Rheumatology, vol. 29, no. 4, pp. 369–373, 2017. View at Publisher · View at Google Scholar · View at Scopus
  70. L. I. Sakkas and D. P. Bogdanos, “Infections as a cause of autoimmune rheumatic diseases,” Autoimmunity Highlights, vol. 7, no. 1, article no. 13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. W. Wu, M. Debbaneh, H. Moslehi, J. Koo, and W. Liao, “Tonsillectomy as a treatment for psoriasis: A review,” Journal of Dermatological Treatment, vol. 25, no. 6, pp. 482–486, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Imafuku, R. Naito, and J. Nakayama, “Possible association of hepatitis C virus infection with late-onset psoriasis: A hospital-based observational study,” The Journal of Dermatology, vol. 40, no. 10, pp. 813–818, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Chun, M. Afshar, D. Audish et al., “Hepatitis C may enhance key amplifiers of psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 4, pp. 672–678, 2017. View at Publisher · View at Google Scholar · View at Scopus
  74. R. G. Foster, L. Golden-Mason, A. Rutebemberwa, and H. R. Rosen, “Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection,” Digestive Diseases and Sciences, vol. 57, no. 2, pp. 381–389, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Brazzelli, A. Carugno, A. Alborghetti et al., “Hepatitis C infection in Italian psoriatic patients: Prevalence and correlation with patient age and psoriasis severity,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 12, pp. 1581-1582, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Sansone, M. Guarino, F. Castiglione et al., “Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease,” World Journal of Gastroenterology, vol. 20, no. 13, pp. 3516–3524, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Mahale, D. P. Kontoyiannis, R. F. Chemaly et al., “Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients,” Journal of Hepatology, vol. 57, no. 6, pp. 1177–1185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Snast, L. Atzmony, M. Braun, E. Hodak, and L. Pavlovsky, “Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature,” Journal of the American Academy of Dermatology, vol. 77, no. 1, pp. 88–97.e5, 2017. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Di Nuzzo, V. Boccaletti, C. Fantini et al., “Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature,” Dermatology, vol. 232, no. 1, pp. 102–106, 2016. View at Publisher · View at Google Scholar · View at Scopus
  80. European Association for the Study of the Liver, “EASL Recommendations on Treatment of Hepatitis C 2016,” Journal of Hepatology, vol. 66, no. 1, pp. 153–194, 2017. View at Publisher · View at Google Scholar
  81. Centers for Disease Control and Prevention, “Testing for HCV infection: an update of guidance for clinicians and laboratorians,” Morbidity and Mortality Weekly Report, vol. 62, no. 18, pp. 362–365, 2013. View at Google Scholar
  82. P. Grewal and R. Sanghera, “Hepatitis B and C Viruses and Biologics,” Skin Therapy Letter, vol. 22, no. 4, pp. 7–9, 2017. View at Google Scholar
  83. I. Gentile, A. E. Maraolo, A. R. Buonomo, E. Zappulo, and G. Borgia, “The discovery of sofosbuvir: A revolution for therapy of chronic hepatitis C,” Expert Opinion on Drug Discovery, vol. 10, no. 12, pp. 1363–1377, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. http://www.hep-druginteractions.org/checker.
  85. K. Eyerich, V. Dimartino, and A. Cavani, “IL-17 and IL-22 in immunity: Driving protection and pathology,” European Journal of Immunology, vol. 47, no. 4, pp. 607–614, 2017. View at Publisher · View at Google Scholar · View at Scopus
  86. X.-F. Wang, Y.-T. Zhu, J.-J. Wang et al., “The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients,” PLoS ONE, vol. 12, no. 9, Article ID e0185168, 2017. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Wang, Y. Wang, X. Feng et al., “Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center,” International Journal of Infectious Diseases, vol. 65, pp. 15–21, 2017. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Li, N. L. Li, D. Wei, S. R. Pfeffer, M. Fan, and L. M. Pfeffer, “Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates,” Hepatology, vol. 55, no. 3, pp. 666–675, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. J.-T. Kao, C.-L. Feng, C.-J. Yu et al., “IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: A cohort study,” BMC Gastroenterology, vol. 15, no. 1, 50 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. Wang, K. Takeishi, Z. Li et al., “Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancy-related hallmarks,” Organogenesis, pp. 1–12, 2017. View at Publisher · View at Google Scholar · View at Scopus
  91. R. D. Leek, C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris, “Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma,” Cancer Research, vol. 56, no. 20, pp. 4625–4629, 1996. View at Google Scholar · View at Scopus
  92. H. Traupe, “Psoriasis and the interleukin-10 family: evidence for a protective genetic effect, but not an easy target as a drug,” British Journal of Dermatology, vol. 176, no. 6, pp. 1438-1439, 2017. View at Publisher · View at Google Scholar · View at Scopus
  93. D. C. B. L. Aroucha, R. F. Do Carmo, P. Moura et al., “High tumor necrosis factor-α/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C,” Cytokine, vol. 62, no. 3, pp. 421–425, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. L. A. Adams, P. Angulo, and K. D. Lindor, “Nonalcoholic fatty liver disease,” Canadian Medical Association Journal, vol. 172, no. 7, pp. 899–905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Zhang, F. Bernuzzi, A. Lleo, X. Ma, and P. Invernizzi, “Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases,” Mediators of Inflammation, vol. 2015, Article ID 436450, 12 pages, 2015. View at Publisher · View at Google Scholar
  96. L. I. Sakkas and D. P. Bogdanos, “Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data,” Autoimmunity Reviews, vol. 16, no. 1, pp. 10–15, 2017. View at Publisher · View at Google Scholar · View at Scopus
  97. E. A. Boström, M. Ekstedt, S. Kechagias, C. Sjöwall, M. I. Bokarewa, and S. Almer, “Resistin is Associated with Breach of Tolerance and Anti-nuclear Antibodies in Patients with Hepatobiliary Inflammation,” Scandinavian Journal of Immunology, vol. 74, no. 5, pp. 463–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. V. Barak, C. Selmi, M. Schlesinger et al., “Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis,” Journal of Autoimmunity, vol. 33, no. 3-4, pp. 178–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. K. Harada, S. Shimoda, Y. Sato, K. Isse, H. Ikeda, and Y. Nakanuma, “Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis,” Clinical & Experimental Immunology, vol. 157, no. 2, pp. 261–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Zhao, S. Zhao, G. Zhou et al., “Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 46, no. 4, pp. 485–494, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. X. Bo, U. Broome, M. Remberger, and S. Sumitran-Holgersson, “Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis,” Gut, vol. 49, no. 1, pp. 131–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Ganzetti, A. Campanati, E. Molinelli, and A. Offidani, “Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background,” World Journal of Cardiology, vol. 8, no. 2, pp. 120–131, 2016. View at Publisher · View at Google Scholar
  103. J. Han, A. L. Dzierlenga, Z. Lu et al., “Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model,” Obesity, vol. 25, no. 6, pp. 1069–1076, 2017. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Kitade, G. Chen, Y. Ni, and T. Ota, “Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments,” Nutrients, vol. 9, no. 4, article no. 387, 2017. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Zeng, S. Luo, Y. Huang, and Q. Lu, “Critical role of environmental factors in the pathogenesis of psoriasis,” The Journal of Dermatology, vol. 44, no. 8, pp. 863–872, 2017. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Sebode, J. Hartl, D. Vergani, and A. W. Lohse, “Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda,” Liver International, vol. 38, no. 1, pp. 15–22, 2018. View at Publisher · View at Google Scholar
  107. C. Rupp, A. Mummelthei, P. Sauer et al., “Non-IBD immunological diseases are a risk factor for reduced survival in PSC,” Liver International, vol. 33, no. 1, pp. 86–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. H. Yu, J. Huang, and Y. Liu, “IL-17 contributes to autoimmune hepatitis,” Journal of Huazhong University of Science and Technology (Medical Sciences), vol. 30, no. 4, pp. 443–446, 2010. View at Publisher · View at Google Scholar
  109. D. Howel, C. M. Fischbacher, R. S. Bhopal, J. Gray, J. V. Metcalf, and O. F. W. James, “An exploratory population-based case-control study of primary biliary cirrhosis,” Hepatology, vol. 31, no. 5, pp. 1055–1060, 2000. View at Publisher · View at Google Scholar · View at Scopus
  110. K. D. Lindor, M. E. Gershwin, R. Poupon, M. Kaplan, N. V. Bergasa, and E. J. Heathcote, “Primary biliary cirrhosis,” Hepatology, vol. 50, no. 1, pp. 291–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. W.-H. Boehncke and M. P. Schön, “Psoriasis,” The Lancet, vol. 386, no. 9997, pp. 983–994, 2015. View at Publisher · View at Google Scholar · View at Scopus
  112. M. I. Prince, S. J. Ducker, and O. F. W. James, “Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations,” Gut, vol. 59, no. 4, pp. 508–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Efe, S. Wahlin, E. Ozaslan et al., “Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases,” European Journal of Gastroenterology & Hepatology, vol. 24, no. 5, pp. 531–534, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Floreani, R. Motta, N. Cazzagon et al., “The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis,” Digestive and Liver Disease, vol. 47, no. 5, pp. 432–435, 2015. View at Publisher · View at Google Scholar · View at Scopus
  115. Y. Shoenfeld and D. A. Isenberg, “The mosaic of autoimmunity,” Trends in Immunology, vol. 10, no. 4, pp. 123–126, 1989. View at Publisher · View at Google Scholar · View at Scopus
  116. V. S. Hegade, S. F. W. Kendrick, R. L. Dobbins et al., “Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study,” The Lancet, vol. 389, no. 10074, pp. 1114–1123, 2017. View at Publisher · View at Google Scholar · View at Scopus
  117. U. Broomé, R. Olsson, L. Lööf et al., “Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis,” Gut, vol. 38, no. 4, pp. 610–615, 1996. View at Publisher · View at Google Scholar · View at Scopus
  118. N. G. Gidwaney, S. Pawa, and K. M. Das, “Pathogenesis and clinical spectrum of primary sclerosing cholangitis,” World Journal of Gastroenterology, vol. 23, no. 14, pp. 2459–2469, 2017. View at Publisher · View at Google Scholar · View at Scopus
  119. G. F. Mells, A. Kaser, and T. H. Karlsen, “Novel insights into autoimmune liver diseases provided by genome-wide association studies,” Journal of Autoimmunity, vol. 46, pp. 41–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. T. A. van der Meulen, H. J. M. Harmsen, H. Bootsma, F. K. L. Spijkervet, F. G. M. Kroese, and A. Vissink, “The microbiome–systemic diseases connection,” Oral Diseases, vol. 22, no. 8, pp. 719–734, 2016. View at Publisher · View at Google Scholar · View at Scopus
  121. Z. Zákostelská, J. Málková, K. Klimešová et al., “Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response,” PLoS ONE, vol. 11, no. 7, p. e0159539, 2016. View at Publisher · View at Google Scholar
  122. M. Allez, M.-E. Roux, P. Bertheau et al., “Recurrent cholestatic jaundice associated with generalized pustular psoriasis: Evidence for a neutrophilic cholangitis,” Journal of Hepatology, vol. 33, no. 1, pp. 160–162, 2000. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Viguier, M. Allez, A.-M. Zagdanski et al., “High frequency of cholestasis in generalized pustular psoriasis: Evidence for neutrophilic involvement of the biliary tract,” Hepatology, vol. 40, no. 2, pp. 452–458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Isse, K. Harada, and Y. Nakanuma, “IL-8 expression by biliary epithelial cells is associated with neutrophilic infiltration and reactive bile ductules,” Liver International, vol. 27, no. 5, pp. 672–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Marrakchi, P. Guigue, B. R. Renshaw et al., “Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis,” The New England Journal of Medicine, vol. 365, no. 7, pp. 620–628, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. D. Kane, J. Roth, M. Frosch, T. Vogl, B. Bresnihan, and O. FitzGerald, “Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis,” Arthritis & Rheumatology, vol. 48, no. 6, pp. 1676–1685, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Karagiannidis, M. Karavalaki, and A. Koulaouzidis, “Hepatic sarcoidosis,” Annals of Hepatology, vol. 5, no. 4, pp. 251–256, 2006. View at Google Scholar · View at Scopus
  128. R. Cuchacovich, J. Hagan, T. Khan, A. Richert, and L. R. Espinoza, “Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): Case report and review of the literature,” Clinical Rheumatology, vol. 30, no. 1, pp. 133–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. W. G. McCluggage and J. M. Sloan, “Hepatic granulomas in Northern Ireland: a thirteen year review,” Histopathology, vol. 25, no. 3, pp. 219–228, 1994. View at Publisher · View at Google Scholar · View at Scopus
  130. K. Vu, J. Atkinson, and P. Ranganathan, “Bone Lesions, Lymphadenopathy, and Hepatic Granulomas in a Patient with Psoriasis,” Arthritis Care & Research, vol. 68, no. 3, pp. 394–399, 2016. View at Publisher · View at Google Scholar · View at Scopus